Apyx Medical Corporation raised its fiscal 2026 revenue outlook to between $59 million and $60 million [1].
The update reflects a surge in demand for the company's AYON Surgical Aesthetics products, signaling a shift in the company's growth trajectory through its specialized medical devices.
During an earnings call on May 8, President, CEO and Director Charles Goodwin said that the new guidance is a revision upward from the previous range of $57.5 million to $58.5 million [1]. This adjustment follows a strong performance in the first quarter of fiscal 2026, where the company reported total quarterly revenue of $12.5 million [2].
In the same period last year, the company reported $9.4 million in total revenue [3]. Goodwin said, "This growth was driven by a 36% increase in sales of our Surgical Aesthetics products" [3].
The company's revised annual expectations are heavily weighted toward its aesthetics division. Revenue guidance for the Surgical Aesthetics segment for 2026 is set between $54 million and $55 million [1]. Meanwhile, the OEM segment is expected to generate approximately $5 million [1].
Goodwin said the company reported total quarterly revenue of $12.5 million compared to $9.4 million in the same period last year [3]. The ramp in AYON demand has become the primary catalyst for the updated financial projections as the company enters the second quarter.
“This growth was driven by a 36% increase in sales of our Surgical Aesthetics products.”
The upward revision of the 2026 outlook indicates that Apyx Medical is successfully pivoting its revenue stream toward the high-growth surgical aesthetics market. With the Surgical Aesthetics segment now accounting for the vast majority of the company's projected annual revenue, the firm's financial health is increasingly tied to the market adoption of the AYON product line rather than its OEM operations.
